Immunotherapy combo shows promise for inoperable esophageal cancer
NCT ID NCT03777813
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested whether adding the immunotherapy drug durvalumab to standard chemoradiation (FOLFOX and radiation) helps patients with unresectable esophageal cancer. 112 patients were randomly assigned to receive either chemoradiation alone or chemoradiation plus durvalumab, followed by maintenance durvalumab. The study measured progression-free survival, overall survival, side effects, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Durvalumab (an immunotherapy drug) plus chemotherapy (FOLFOX) and radiation therapy
What this could lead to
If successful, this combination could improve control of unresectable esophageal cancer and extend survival without the need for surgery.
What could go wrong
This is a Phase 2 trial with only 112 participants, so results are preliminary. The added immunotherapy may increase side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Rangueil Larrey
Toulouse, France
-
Centre Hospitalier Universitaire
Poitiers, France
-
Centre Oscar Lambret, CLCC UNICANCER
Lille, France
-
Centre Paul Strauss, CLCC UNICANCER
Strasbourg, France
-
Hôpital Haut-Lévêque
Pessac, 33604, France
-
Hôpital Saint Louis, APHP
Paris, 75010, France
-
Iuct, Clcc Unicancer
Toulouse, 31059, France